After a second wave of intensive household testing, a large study of the 'test and treat' strategy in Zambia is diagnosing more people with HIV, getting more people onto treatment and reducing the time between diagnosis and starting treatment, findings from the PopART study presented last month at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) show.
PopART, also known as HPTN 071, is a large community-randomised trial being carried out in Zambia and KwaZulu-Natal, South Africa. The study is comparing the impact on HIV incidence of household-based HIV testing and linkage to care by community HIV care providers (CHiPs), and immediate initiation of antiretroviral treatment delivered through routine health care services, to the standard of care.
PopART is an important test of the feasibility of offering testing and treatment at a very large scale, essential for achievement of the 90-90-90 target of 90% of people with HIV diagnosed, 90% of diagnosed people on treatment and 90% of those on treatment virally suppressed.
PopART investigators reported on progress towards achieving the 90-90-90 goals in the second round of the study in Zambia, from June 2015 to October 2016 in communities randomised to receive household visits. Each round of the study consists of visits to all households in the community to offer home-based HIV counselling and testing and, in round two, to make contact with everyone diagnosed with HIV in round one, to ensure that they had been linked to care and remain in HIV care.
After the first round of the study, 53% of people diagnosed with HIV in Zambia had started treatment within 12 months.
In Round Two, 45,616 households were visited, and 95% consented to take part in the study, comprising 110,755 adults (65% of men and 87% of women actually underwent testing). The higher frequency of testing among women was due to the fact that women were more likely to be contacted at home than men.
The researchers produced an estimate for the total number of adults living with HIV based on the prevalence of HIV among those who were tested (9.8% in men and 16.1% in women). They concluded that 6249 men and 10,341 women were living with HIV, and that 78% of men with HIV and 90% of women with HIV had been diagnosed.
Although men with HIV remained less likely to be diagnosed than women after Round Two, there was substantial improvement in the level of diagnosis in men. By the end of Round Two the proportion of men in all age bands diagnosed with HIV had risen above 70%, compared to less than 60% of those in the under-35 age bands being diagnosed after Round One. Men over 40 remained more likely to be aware of their HIV status after Round Two.
Among women the age difference in diagnosis evident after the first round had largely disappeared after Round Two. Almost 90% of women knew their HIV status in all age bands after Round Two.
After Round Two 78% of diagnosed men and 79% of women were estimated to be taking antiretroviral therapy (ART). Young men and women were less likely to be on treatment, but uptake of treatment improved in both women and men in Round Two. Among those who reported that they had started ART prior to the beginning of Round Two, 92% of men and 95% of women were still taking ART at the time they were contacted to take part in Round Two.
The speed at which people started treatment after having been referred for HIV care also improved in Round Two. Whereas it took study participants a median of nine and a half months to start treatment after referral in Round One, this interval was reduced to five months in Round Two. The investigators attribute this improvement to an increased focus among community HIV care providers on ensuring linkage to care, and improved co-ordination with clinics to ensure linkage.
Hayes R et al. Reaching 90-90-90? Findings after two years of HTPN 071 (PopART) intervention in Zambia. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, abstract 1011, 2017.
Floyd S et al. ART coverage after two years of a UTT intervention in Zambia: findings from HPTN071. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, abstract 1010, 2017.